Cargando…
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modifie...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962407/ https://www.ncbi.nlm.nih.gov/pubmed/27460100 http://dx.doi.org/10.1186/s12876-016-0490-8 |
_version_ | 1782444828749987840 |
---|---|
author | Lee, Ju Yup Kim, Nayoung Park, Kyung Sik Kim, Hyun Jin Park, Seon Mee Baik, Gwang Ho Shim, Ki-Nam Oh, Jung Hwan Choi, Suck Chei Kim, Sung Eun Kim, Won Hee Park, Seon-Young Kim, Gwang Ha Lee, Bong Eun Jo, Yunju Hong, Su Jin |
author_facet | Lee, Ju Yup Kim, Nayoung Park, Kyung Sik Kim, Hyun Jin Park, Seon Mee Baik, Gwang Ho Shim, Ki-Nam Oh, Jung Hwan Choi, Suck Chei Kim, Sung Eun Kim, Won Hee Park, Seon-Young Kim, Gwang Ha Lee, Bong Eun Jo, Yunju Hong, Su Jin |
author_sort | Lee, Ju Yup |
collection | PubMed |
description | BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy. METHODS: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). (13)C-urea breath test, rapid urease testing, or histology was performed to check for eradication. RESULTS: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040). CONCLUSIONS: Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02159976); Registration date: 2014-06-03, CRIS (KCT0001176); Registration date: 2014-07-23. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-016-0490-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4962407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49624072016-07-28 Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial Lee, Ju Yup Kim, Nayoung Park, Kyung Sik Kim, Hyun Jin Park, Seon Mee Baik, Gwang Ho Shim, Ki-Nam Oh, Jung Hwan Choi, Suck Chei Kim, Sung Eun Kim, Won Hee Park, Seon-Young Kim, Gwang Ha Lee, Bong Eun Jo, Yunju Hong, Su Jin BMC Gastroenterol Research Article BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy. METHODS: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). (13)C-urea breath test, rapid urease testing, or histology was performed to check for eradication. RESULTS: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040). CONCLUSIONS: Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02159976); Registration date: 2014-06-03, CRIS (KCT0001176); Registration date: 2014-07-23. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-016-0490-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4962407/ /pubmed/27460100 http://dx.doi.org/10.1186/s12876-016-0490-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lee, Ju Yup Kim, Nayoung Park, Kyung Sik Kim, Hyun Jin Park, Seon Mee Baik, Gwang Ho Shim, Ki-Nam Oh, Jung Hwan Choi, Suck Chei Kim, Sung Eun Kim, Won Hee Park, Seon-Young Kim, Gwang Ha Lee, Bong Eun Jo, Yunju Hong, Su Jin Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title | Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title_full | Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title_fullStr | Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title_full_unstemmed | Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title_short | Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial |
title_sort | comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of helicobacter pylori: a prospective, multi-center, randomized clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962407/ https://www.ncbi.nlm.nih.gov/pubmed/27460100 http://dx.doi.org/10.1186/s12876-016-0490-8 |
work_keys_str_mv | AT leejuyup comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT kimnayoung comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT parkkyungsik comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT kimhyunjin comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT parkseonmee comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT baikgwangho comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT shimkinam comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT ohjunghwan comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT choisuckchei comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT kimsungeun comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT kimwonhee comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT parkseonyoung comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT kimgwangha comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT leebongeun comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT joyunju comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial AT hongsujin comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial |